Advertisement

Topics

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

2018-09-19 05:14:17 | BioPortfolio

Published on BioPortfolio: 2018-09-19T05:14:17-0400

Clinical Trials [442 Associated Clinical Trials listed on BioPortfolio]

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

This is a prospective randomized, double-blind, placebo-controlled study in subjects with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

This is a prospective, randomized, open-label study in subjects with migraine who have completed CoLucid Phase 3 study, COL MIG 301 or COL MIG-302. The study is designed to evaluate the sa...

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects

This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 ...

A Study of Lasmiditan in Participants With Migraine

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the ...

A Study of Lasmiditan on the Heart in Healthy Participants

The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream an...

PubMed Articles [1046 Associated PubMed Articles listed on BioPortfolio]

The Migraine Postdrome.

The migraine postdrome is the least studied and least understood phase of migraine. This article covers the salient features of the migraine postdrome and provides insight into the history, clinical s...

Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application.

Migraine is a neurological disease characterized by recurring attacks that can cause severe disabling pain. This study described the burden of migraine as reported by individuals with migraine in the ...

White matter tract microstructure of the mPFC-amygdala predicts interindividual differences in placebo response related to treatment in migraine patients.

To investigate whether interindividual variability of white matter (WM) tract microstructure of the medial prefrontal cortex (mPFC)-amygdala circuit could predict 8-week placebo treatment outcomes in ...

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.

To characterize adult patients with episodic migraine who achieved 100% response to galcanezumab treatment.

Headache: Migraine.

Migraine is a primary headache disorder and a common, recurrent, disabling condition that affects an estimated 18% of women and 6% of men. Commonly reported triggers that induce migraine include stres...

Medical and Biotech [MESH] Definitions

A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

Serotonin antagonist used against MIGRAINE DISORDERS and vascular headaches.

More From BioPortfolio on "A Study of Lasmiditan (LY573144) Over Four Migraine Attacks"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial